MERCK LIFE SCIENCE AS
Score · fiscal year 2025
70of 100
How to read this: the company is ahead of 88 % of medium-sized companies in the same sector in 2025. What does this mean?
Rank: 4,847 of 38,671 · Handel
Profile
Lion · Leader
High profitability, high solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 75 and solidity 88 out of 100 among medium-sized companies in the same sector in 2025. Methodology
Against the sector
MERCK LIFE SCIENCE AS is 21 points above the median for medium-sized companies in the same sector in 2025.
Median score 49 among 2,198 companies.
Against medium-sized companies in the same sector in 2025: operating margin 5.7% (median 3.2%) and equity ratio 71.4% (median 32.6%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 169 MNOK | 173 MNOK |
| Operating margin | 5.7% | 3.2% |
| Profit margin | 7.0% | 3.2% |
| Return on assets | 20.6% | 11.6% |
| Equity ratio | 71.4% | 32.6% |
| Debt-to-equity | 0.40 | 2.03 |
| Current ratio | 3.49 | 1.38 |
| Revenue growth | −1.1% | 6.8% |
| Revenue per employee | 16.86 MNOK | 6.45 MNOK |
The median and “ahead of” refer to medium-sized companies in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 70, MERCK LIFE SCIENCE AS does better than 88% of medium-sized companies in the same sector (2,203 companies) in 2025.
Score 2023–2025
- MERCK LIFE SCIENCE AS
- Median: medium-sized companies in the same sector
MERCK LIFE SCIENCE AS has a score of 70 for 2025, rank 4,847 of 38,671 in the sector.
Strongest: Liquidity: percentile 91 against peers, current ratio 3.49 against a median of 1.38. Solidity: percentile 88 against peers, equity ratio 71.4% against a median of 32.6%.
Weakest: Growth: percentile 23 against peers, revenue growth −1.1% against a median of 6.8%.
Worth a closer look
- What lies behind weak growth, and will it last?
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
What the numbers say
MERCK LIFE SCIENCE AS had an operating margin of 5.7% and an equity ratio of 71.4% in 2025, and ranks 4,847 of 38,671 in Handel.
From 2024 to 2025: the equity ratio rose from 29.2% to 71.4%.
This text is generated automatically from the 2025 accounts.
Three simple methods
The methods give between 41 MNOK and 92 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 92 MNOK |
| EV/EBIT | 8.0 | 80 MNOK |
| P/B | 1.0 | 41 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
No rules were triggered for this year.
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 0.3% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2017, the sector's weakest year, for this company.
The sector's weakest year was 2017, with a median operating margin of −65.6%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 75 | weight 30% |
|---|---|---|
| Solidity | 88 | weight 25% |
| Liquidity | 91 | weight 15% |
| Growth | 23 | weight 15% |
| Consistency | 59 | weight 15% |
Durability: 66 (average over 3 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is MERCK LIFE SCIENCE AS?
The operating margin was 5.7% in 2025, against a median of 3.2% among medium-sized companies in the same sector. Return on assets was 20.6%.
How solid is MERCK LIFE SCIENCE AS?
The equity ratio was 71.4% in 2025 (median 32.6%). Debt-to-equity was 0.40 (median 2.03).
What is the liquidity of MERCK LIFE SCIENCE AS like?
The current ratio was 3.49 in 2025 (median 1.38).
How does MERCK LIFE SCIENCE AS compare in Handel?
MERCK LIFE SCIENCE AS ranks 4,847 of 38,671 in Handel for 2025. Among companies of the same size (medium-sized companies) it ranks 255 of 2,203. Revenue changed by −1.1% from the year before.
Group accounts
The company is registered as part of a group, but we have no group accounts for it. Group accounts are filed by the parent company, and open data does not say which company that is.
Read the figures with care: a company in a group can look strong because of group contributions, or weak because dividends go up to the parent. The figures are indications, not the full picture.
We do not show the group structure, because open data does not say who owns whom.
Public contracts
- Contracts awarded since 2024
- 8
- in 6 notices (lots counted separately)
- Total awarded value since 2024
- 10.0 MNOK
- 2 contracts without a stated value are not in the total.
- Framework agreements
- 5
- Left out of the total: the value is a ceiling, not actual spend.
| Date | Buyer | Notice | Value |
|---|---|---|---|
| 17 September 2026 | UNIVERSITETET I BERGEN | ANSK-25-0644 Rammeavtale Laboratorierekvisita og småutstyr til lab | 75.0 MNOK (framework) |
| 1 June 2026 | UNIVERSITETET I BERGEN | ANSK-24-0309 Rammeavtale kjemikalier til dyrking av celler og mikroorganismer | 14.0 MNOK (framework) |
| 28 September 2025 | UiT Norges arktiske universitet | Rammeavtale kjemikalier | 10.0 MNOK |
| 11 April 2025 | SYKEHUSINNKJØP HF | Kontraktstildeling: SPE-plater til analyse av 25-OH Vitamin D på Hormonlaboratoriet ved Oslo universitetssykehus HF | value not stated |
| 26 March 2025 | NORCE Norwegian Research Centre | Forbruksmateriell til lab og kjemikalier, rammeavtale | value not stated (2 lots) |
| 13 March 2024 | NTNU | Kjemikalier Rammeavtale | value not stated (2 lots) |
| 6 December 2023 | UNIVERSITETET I BERGEN | ANSK-22-0326 Rammeavtale kjemikalier (hovedavtale) | value not stated |
| 23 December 2021 | Norges miljø- og biovitenskapelige universitet | Rammeavtale kjemikalier og stoffer | value not stated |
| 26 October 2021 | UiT Norges arktiske universitet | Kjemikalier - rammeavtale | value not stated |
| 7 November 2020 | Norges miljø- og biovitenskapelige universitet | Parallelle rammeavtaler laboratorierekvisita | value not stated |
Based on notices in Doffin. Does not show call-offs under framework agreements or purchases below the publication threshold. Values are as stated by the buyer.
Source: Doffin (DFØ), fetched 28 October 2026. Winners are matched on organisation number.
Contains data under the Norwegian licence for public data (NLOD 2.0) made available by Doffin/the Norwegian Agency for Public and Financial Management (DFØ). NLOD 2.0
From the Central Coordinating Register
- Org. no.
- 976145801
- Legal form
- AS · part of a group
- Sector
- Handel (46.850)
- Size tier
- medium
- Employees
- 10 registered 10 November 2024
- Founded
- 28 February 1996 30 years in operation
- Share capital
- 12.50 MNOK
- Business address
- Drammensveien 123, 0277 OSLO
- Municipality
- Oslo rank 106–282 of 357 in Norway
- Latest accounts filed
- 2025
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
- Chief executive
- Silje Margrethe Skogtrø Braaten
- Chair of the board
- Silje Margrethe Skogtrø Braaten
- Board member
- Martin Sunde Liavåg-Andresen
- Board member
- Tiina Marjatta Puhakka
- Auditor
- DELOITTE AS
- Accountant
- PWC TAX SERVICES AS
Source: Central Coordinating Register, fetched 25 October 2026. Only names are shown.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 28 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 81 | 46 | 70 | |
| Rank | 2,076 | 21,385 | 4,847 | |
| Operating margin | 5.3% | 7.0% | 5.7% | |
| Return on assets | 11.9% | 14.0% | 20.6% | |
| Equity ratio | 77.6% | 29.2% | 71.4% | |
| Current ratio | 4.47 | 1.41 | 3.49 | |
| Revenue growth | – | −9.7% | −1.1% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 188.9 MNOK | 170.5 MNOK | 168.6 MNOK |
| Operating profit | 10.1 MNOK | 11.9 MNOK | 9.7 MNOK |
| Profit before tax | 11.4 MNOK | 15.2 MNOK | 11.9 MNOK |
| Net profit | 8.8 MNOK | 11.8 MNOK | 9.2 MNOK |
| Financial expenses | 0.5 MNOK | 0.3 MNOK | 0.1 MNOK |
| Total assets | 99.7 MNOK | 110.5 MNOK | 58.0 MNOK |
| Current assets | 99.7 MNOK | 110.3 MNOK | 57.9 MNOK |
| Equity | 77.4 MNOK | 32.2 MNOK | 41.4 MNOK |
| Retained earnings | 64.3 MNOK | 19.1 MNOK | 28.3 MNOK |
| Total liabilities | 22.3 MNOK | 78.3 MNOK | 16.6 MNOK |
| Current liabilities | 22.3 MNOK | 78.3 MNOK | 16.6 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 28 October 2026, accounts id 6835414.
Further
Similar companies
- Erling Sande A/S index 70, rank 4,783 · compare
- HALVOR BJERKE AS index 70, rank 4,792 · compare
- ABBVIE AS index 70, rank 4,820 · compare
- EUROPRESS AS index 70, rank 4,856 · compare
- BPW HOFSTAD AS index 70, rank 4,864 · compare